Search...
Mizuho Securities Sticks to Their Buy Rating for Vaxcyte (PCVX)
I'm PortAI, I can summarize articles.
Mizuho Securities analyst Salim Syed maintained a Buy rating for Vaxcyte, setting a price target of $163.00. Syed, who covers the Healthcare sector, has an average return of -4.1% and a 41.09% success rate. Vaxcyte holds a Strong Buy consensus among analysts, with a consensus price target of $90.33.
Mizuho Securities analyst Salim Syed maintained a Buy rating on Vaxcyte today and set a price target of $163.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Syed covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Atara Biotherapeutics, and Assembly Biosciences. According to TipRanks, Syed has an average return of -4.1% and a 41.09% success rate on recommended stocks.
Vaxcyte has an analyst consensus of Strong Buy, with a price target consensus of $90.33.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments